AbbVie ABBV Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.7%+0.4pp | 70.2%+0.5pp | 69.7%-1.2pp | 70.9%+0.2pp | 70.7%+0.7pp | |
| Operating margin | 24.4%-0.2pp | 24.6%— | —— | —— | —— | |
| Net margin | 5.8%-1.1pp | 6.9%+2.9pp | 4%-2.4pp | 6.5%-0.9pp | 7.3%-0.3pp | |
| EBITDA margin | 37.3%-0.8pp | 38.1%— | —— | —— | —— | |
| Free cash flow margin | 31.8%+2.7pp | 29.1%-3.9pp | 33%+1.7pp | 31.3%+4.5pp | 26.8%-4.8pp | |
| Returns | ||||||
| Return on assets | 2.7%-0.5pp | 3.1%+1.4pp | 1.7%-1.0pp | 2.7%-0.2pp | 2.9%-0.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 3.8×-0.1× | 4×+0.1× | 3.8×+0.1× | 3.7×-0.1× | 3.8×-0.2× | |
| Liquidity | ||||||
| Current ratio | 0.8×+0.1× | 0.7×-0.1× | 0.7×0.0× | 0.7×0.0× | 0.8×+0.1× | |
| Quick ratio | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×+0.1× | |
| Cash ratio | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | -$3.75-103% | -$1.84-23.7% | -$1.49-1,343% | -$0.10-113% | $0.80-57.3% | |
| Valuation | ||||||
| Market capitalization | $384.69B-4.7% | $403.83B-1.3% | $409.03B+24.8% | $327.76B-11.6% | $370.64B+18.0% | |
| Price / earnings | 105.8×+10.3× | 95.6×-75.7× | 171.3×+84.2× | 87.1×-1.3× | 88.4×+14.9× | |
| Price / sales | 6.1×-0.5× | 6.6×-0.3× | 6.9×+1.2× | 5.6×-0.8× | 6.5×+0.9× | |
| Free cash flow yield | 5.2%+0.8pp | 4.4%-0.4pp | 4.8%-0.8pp | 5.6%+1.4pp | 4.2%-1.5pp | |
| Earnings yield | 0.9%-0.1pp | 1%+0.5pp | 0.6%-0.6pp | 1.1%0.0pp | 1.1%-0.2pp | |
| Dividend yield | 3.1%+0.2pp | 2.9%+0.1pp | 2.8%-0.6pp | 3.5%+0.4pp | 3%-0.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are AbbVie's profit margins?
- AbbVie (ABBV) runs a 70.7% gross margin and a 24.4% operating margin, with a 5.8% net margin.
- Where do AbbVie's ratios come from?
- Every ratio is computed from AbbVie's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
